Colchicine in Coronary Artery Bypass Graft (CABG)

Phase 4 Completed 60 enrolled G.Gennimatas General Hospital Evangelismos Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.

Timeline

Start: 2013-11
Primary completion: 2014-06
Completion: 2014-11

Outcome

Met primary endpoint

paper Maximal hsTnT was 616 pg/ml (396 to 986) in the colchicine group versus 1,613 pg/ml (732 to 2,587) in controls (p = 0.002). PMID 25784519 ↗

Publications

Giannopoulos G, Angelidis C, Kouritas VK, Dedeilias P, Filippatos G, Cleman MW, Panagopoulou V, Siasos G, Tousoulis D, Lekakis J, Deftereos S. Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol. 2015 May 15;115(10):1376-81. doi: 10.1016/j.amjcard.2015.02.036. Epub 2015 Feb 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Colchicine	Small molecule	0.5 mg	Oral

Indications

No indication recorded.